Piperlongumine and immune cytokine TRAIL synergize to promote tumor death

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Li, Jiahe ^a   Sharkey, Charles C ^a   King, Michael R ^a  

^a Cornell University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 DIOXOLANE DERIVATIVE; ANTINEOPLASTIC AGENT; MITOGEN ACTIVATED PROTEIN KINASE; PIPERLONGUMININE; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

AGONISTS; ANIMAL; APOPTOSIS; CELL DEATH; DISEASE MODEL; DRUG EFFECTS; DRUG POTENTIATION; DRUG SCREENING; FEMALE; HUMAN; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DEATH; CELL LINE, TUMOR; DIOXOLANES; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; FEMALE; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; REACTIVE OXYGEN SPECIES; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRIPLE NEGATIVE BREAST NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84929600877     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep09987     Document Type: Article

References (40)

1. Mitchison, T. J. The proliferation rate paradox in antimitotic chemotherapy. Mol. Biol. Cell 23, 1-6, doi: Doi 10.1091/Mbc. E10-04-0335 (2012).
2. Galmarini, C. M., Mackey, J. R. & Dumontet, C. Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia 15, 875-890, doi: Doi 10.1038/Sj. Leu.2402114 (2001).
3. Harbeck, N., Ewer, M. S., De Laurentiis, M., Suter, T. M. & Ewer, S. M. Cardiovascular complications of conventional and targeted adjuvant breast cancer therapy. Ann. Oncol. 22, 1250-1258, doi: Doi 10.1093/Annonc/Mdq543 (2011).
4. Yeh, E. T. H. & Bickford, C. L. Cardiovascular Complications of Cancer Therapy Incidence, Pathogenesis, Diagnosis, and Management. J. Am. Coll. Cardiol. 53, 2231-2247, doi: Doi 10.1016/J. Jacc.2009.02.050 (2009).
5. Yeh, E. T. H. et al. Cardiovascular complications of cancer therapy - Diagnosis, pathogenesis, and management. Circulation 109, 3122-3131, doi: Doi 10.1161/01. Cir.0000133187.74800. B9 (2004).
6. Logue, J. S. & Morrison, D. K. Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy. Gene. Dev. 26, 641-650, doi: Doi 10.1101/Gad.186965.112 (2012).
7. Yingling, J. M., Blanchard, K. L. & Sawyer, J. S. Development of TGF-beta signalling inhibitors for cancer therapy. Nat. Rev. Drug Discov. 3, 1011-1022, doi: Doi 10.1038/Nrd1580 (2004).
8. Koivisto, P. et al. Androgen receptor gene amplification: A possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res. 57, 314-319 (1997).
9. Spector, N., Xia, W. L., El-Hariry, I., Yarden, Y. & Bacus, S. Small molecule HER-2 tyrosine kinase inhibitors. Breast Cancer Res. 9, doi: Artn 205 Doi 10.1186/Bcr1652 (2007).
10. Slamon, D. J. et al. Human-Breast Cancer - Correlation of Relapse and Survival with Amplification of the Her-2 Neu Oncogene. Science 235, 177-182, doi: Doi 10.1126/Science.3798106 (1987).
11. Trachootham, D., Alexandre, J. & Huang, P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat. Rev. Drug Discov. 8, 579-591, doi: Doi 10.1038/Nrd2803 (2009).
12. Schumacker, P. T. Reactive oxygen species in cancer cells: Live by the sword, die by the sword. Cancer Cell 10, 175-176, doi: Doi 10.1016/J. Ccr.2006.08.015 (2006).
13. Raj, L. et al. Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature 475, 231-234, doi: Doi 10.1038/Nature10167 (2011).
14. Wang, Y. et al. Piperlongumine induces autophagy by targeting p38 signaling. Cell Death Dis. 4, e824, doi:10.1038/cddis.2013.358 (2013).
15. Komarova, N. L. & Wodarz, D. Drug resistance in cancer: Principles of emergence and prevention. P. Natl. Acad. Sci. USA 102, 9714-9719, doi: Doi 10.1073/Pnas.0501870102 (2005).
16. Tang, J. et al. Target Inhibition Networks: Predicting Selective Combinations of Druggable Targets to Block Cancer Survival Pathways. Plos Comput. Biol. 9, doi: Artn E1003226 Doi 10.1371/Journal. Pcbi.1003226 (2013).
17. Wang, H., Li, F., Du, C., Mahato, R. I. & Huang, Y. Doxorubicin and Lapatinib Combination Nanomedicine for Treating Resistant Breast Cancer. Mol. Pharm. doi:10.1021/mp400687w (2014).
18. Bellail, A. C., Qi, L., Mulligan, P., Chhabra, V. & Hao, C. TRAIL agonists on clinical trials for cancer therapy: the promises and the challenges. Rev. Recent Clin. Trials 4, 34-41 (2009).
19. Wang, S. & El-Deiry, W. S. TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 22, 8628-8633, doi:10.1038/sj.onc.1207232 (2003).
20. Wang, S. The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway. Oncogene 27, 6207-6215, doi:10.1038/onc.2008.298 (2008).
21. Mitchell, M. J., Wayne, E., Rana, K., Schaffer, C. B. & King, M. R. TRAIL-coated leukocytes that kill cancer cells in the circulation. P. Natl. Acad. Sci. USA 111, 930-935, doi:10.1073/pnas.1316312111 (2014).
22. Dimberg, L. Y. et al. On the TRAIL to successful cancer therapy?Predicting and counteracting resistance against TRAIL-based therapeutics. Oncogene 32, 1341-1350, doi: Doi 10.1038/Onc.2012.164 (2013).
23. Choo, M. K. et al. Blockade of transforming growth factor-beta-activated kinase 1 activity enhances TRAIL-induced apoptosis through activation of a caspase cascade. Mol. Cancer Ther. 5, 2970-2976, doi: Doi 10.1158/1535-7163. Mct-06-0379 (2006).
24. Szegezdi, E., Cahill, S., Meyer, M., O'Dwyer, M. & Samali, A. TRAIL sensitisation by arsenic trioxide is caspase-8 dependent and involves modulation of death receptor components and Akt. Brit. J. Cancer 94, 398-406, doi: Doi 10.1038/Sj. Bjc.6602954 (2006).
25. Jia, Y. T. et al. Activation of p38 MAPK by reactive oxygen species is essential in a rat model of stress-induced gastric mucosal injury. J. Immunol. 179, 7808-7819 (2007).
26. Cowan, K. J. & Storey, K. B. Mitogen-activated protein kinases: new signaling pathways functioning in cellular responses to environmental stress. J. Exp. Biol. 206, 1107-1115, doi: Doi 10.1242/Jeb.00220 (2003).
27. Criscitiello, C., Azim, H. A., Schouten, P. C., Linn, S. C. & Sotiriou, C. Understanding the biology of triple-negative breast cancer. Ann. Oncol. 23, 13-18, doi: Doi 10.1093/Annonc/Mds188 (2012).
28. Crown, J., O'Shaughnessy, J. & Gullo, G. Emerging targeted therapies in triple-negative breast cancer. Ann. Oncol. 23, 56-65, doi: Doi 10.1093/Annonc/Mds196 (2012).
29. Wang, S. et al. Doxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanisms. intermediacy of H (2) O (2) - and p53-dependent pathways. J. Biol. Chem. 279, 25535-25543, doi:10.1074/jbc. M400944200 (2004).
30. Praga, C., Beretta, G. & Labianca, R. Cardiac toxicity from antitumor therapy. Oncology 37(Suppl 1), 51-58 (1980).
31. Chlebowski, R. T. Adriamycin (doxorubicin) cardiotoxicity: a review. West J. Med. 131, 364-368 (1979).
32. Cobleigh, M. A. Other Options in the Treatment of Advanced Breast Cancer. Semin Oncol. 38, S11-Ss16, doi: Doi 10.1053/J. Seminoncol.2011.04.005 (2011).
33. Gochi, A., Orita, K., Fuchimoto, S., Tanaka, N. & Ogawa, N. The prognostic advantage of preoperative intratumoral injection of OK-432 for gastric cancer patients. Brit. J. Cancer 84, 443-451, doi: Doi 10.1054/Bjoc.2000.1599 (2001).
34. Han, H. D., Byeon, Y., Jeon, H. N. & Shin, B. C. Enhanced localization of anticancer drug in tumor tissue using polyethylenimineconjugated cationic liposomes. Nanoscale Res. Lett. 9, doi: Artn 209 Doi 10.1186/1556-276x-9-209 (2014).
35. Lammers, T. et al. Effect of intratumoral injection on the biodistribution and the therapeutic potential of HPMA copolymerbased drug delivery systems. Neoplasia 8, 788-795, doi: Doi 10.1593/Neo.06436 (2006).
36. Sersa, G., Stabuc, B., Cemazar, M., Miklavcic, D. & Rudolf, Z. Electrochemotherapy with cisplatin: Clinical experience in malignant melanoma patients. Clin. Cancer Res. 6, 863-867 (2000).
37. Xie, H., Goins, B., Bao, A. D., Wang, Z. J. & Phillips, W. T. Effect of intratumoral administration on biodistribution of Cu-64-labeled nanoshells. Int. J. Nanomed. 7, 2227-2238, doi: Doi 10.2147/Ijn. S30699 (2012).
38. Chae, S. Y. et al. Improved Antitumor Activity and Tumor Targeting of NH2-Terminal-Specific PEGylated Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand. Mol. Cancer Ther. 9, 1719-1729, doi: Doi 10.1158/1535-7163. Mct-09-1076 (2010).
39. Li, J. et al. Human fucosyltransferase 6 enables prostate cancer metastasis to bone. Brit. J. Cancer 109, 3014-3022, doi: Doi 10.1038/Bjc.2013.690 (2013).
40. Gao, F. et al. Ulinastatin Exerts Synergistic Effects with Taxotere and Inhibits Invasion and Metastasis of Breast Cancer by Blocking Angiogenesis and the Epithelial-Mesenchymal Transition. Cancer Biother Radio 28, 218-225, doi: Doi 10.1089/Cbr.2011.1122 (2013).